Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia

Sangeetha Venugopal; Abhishek Maiti; Courtney D. DiNardo; Sanam Loghavi; Naval G. Daver; Tapan M. Kadia; Caitlin R. Rausch; Yesid Alvarado; Maro Ohanian; Koji Sasaki; Nicholas J. Short; Koichi Takahashi; Musa Yilmaz; Farhad Ravandi; Hagop M. Kantarjian; Marina Konopleva

doi:10.1002/ajh.26122

Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia

Sangeetha Venugopal, Abhishek Maiti, Courtney D. DiNardo, Sanam Loghavi, Naval G. Daver, Tapan M. Kadia, Caitlin R. Rausch, Yesid Alvarado, Maro Ohanian, Koji Sasaki, Nicholas J. Short, Koichi Takahashi, Musa Yilmaz, Farhad Ravandi, Hagop M. Kantarjian, Marina Konopleva

Research output: Contribution to journal › Letter › peer-review

24 Scopus citations

Original language	English (US)
Pages (from-to)	E154-E157
Journal	American journal of hematology
Volume	96
Issue number	5
DOIs	https://doi.org/10.1002/ajh.26122
State	Published - May 1 2021

ASJC Scopus subject areas

Hematology

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.1002/ajh.26122

Cite this

Venugopal, S., Maiti, A., DiNardo, C. D., Loghavi, S., Daver, N. G., Kadia, T. M., Rausch, C. R., Alvarado, Y., Ohanian, M., Sasaki, K., Short, N. J., Takahashi, K., Yilmaz, M., Ravandi, F., Kantarjian, H. M., & Konopleva, M. (2021). Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. American journal of hematology, 96(5), E154-E157. https://doi.org/10.1002/ajh.26122

Venugopal, S, Maiti, A , DiNardo, CD , Loghavi, S , Daver, NG , Kadia, TM , Rausch, CR , Alvarado, Y , Ohanian, M , Sasaki, K , Short, NJ , Takahashi, K , Yilmaz, M , Ravandi, F , Kantarjian, HM & Konopleva, M 2021, 'Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia', American journal of hematology, vol. 96, no. 5, pp. E154-E157. https://doi.org/10.1002/ajh.26122

@article{6eb052b56925472ca586516fe1caaf55,

title = "Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia",

author = "Sangeetha Venugopal and Abhishek Maiti and DiNardo, {Courtney D.} and Sanam Loghavi and Daver, {Naval G.} and Kadia, {Tapan M.} and Rausch, {Caitlin R.} and Yesid Alvarado and Maro Ohanian and Koji Sasaki and Short, {Nicholas J.} and Koichi Takahashi and Musa Yilmaz and Farhad Ravandi and Kantarjian, {Hagop M.} and Marina Konopleva",

note = "Funding Information: SV: None. AM: Research funding from Celgene Corporation. CDD: Personal fees from Abbvie, personal fees from Agios, personal fees from Novartis, personal fees from ImmuneOnc, personal fees from Daiichi Sankyo, personal fees from Celgene, personal fees from Jazz, personal fees from Notable Labs, outside the submitted work. SL: None. NGD: reports grant from Abbvie, Genentech, Astellas, Daiichi‐Sankyo, Pfizer, BMS, Immunogen, Novimmune, Forty‐seven; personal fees from Abbvie, Genentech, Astellas, Daiichi‐Sankyo, Pfizer, BMS, Immunogen, Jazz pharmaceuticals, Trillium, Forty‐seven, Gilead, Kite, Novartis. TMK: None. CRR: None. YA: None. MO: None. KS: None. NJS: reports grant from Takeda Oncology, Astellas; Personal fees from Takeda Oncology, AstraZeneca, Amgen. KT: has received personal fees for service on advisory boards of Symbio Pharmaceuticals, GSK, Celgene. MY: None. FR: None. HMK: grants and other from AbbVie, grants and other from Agios, grants and other from Amgen, grants from Ariad, grants from Astex, grants from BMS, from Cyclacel, grants from Daiichi‐Sankyo, grants and other from Immunogen, grants from Jazz Pharma, grants from Novartis, grants and other from Pfizer, other from Actinium, other from Takeda, outside the submitted work. MYK: has received grants from NIH, NCI, Abbvie, Genentech, Stemline Therapeutics, Forty‐Seven, Eli Lilly, Cellectis, Calithera, Ablynx, Astra Zeneca; Consulting/honorarium from AbbVie, Genentech, F. Hoffman La‐Roche, Stemline Therapeutics, Amgen, Forty‐Seven, Kisoji; clinical trial support from Ascentage; stocks/royalties in Reata Pharmaceutical. Funding Information: This study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 from the National Cancer Institute and the Research Project Grant Program (R01CA235622) from the National Institutes of Health. We thank the patients, their caregivers, and members of the study team involved in this trial. ",

year = "2021",

month = may,

day = "1",

doi = "10.1002/ajh.26122",

language = "English (US)",

volume = "96",

pages = "E154--E157",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia

AU - Venugopal, Sangeetha

AU - Maiti, Abhishek

AU - DiNardo, Courtney D.

AU - Loghavi, Sanam

AU - Daver, Naval G.

AU - Kadia, Tapan M.

AU - Rausch, Caitlin R.

AU - Alvarado, Yesid

AU - Ohanian, Maro

AU - Sasaki, Koji

AU - Short, Nicholas J.

AU - Takahashi, Koichi

AU - Yilmaz, Musa

AU - Ravandi, Farhad

AU - Kantarjian, Hagop M.

AU - Konopleva, Marina

N1 - Funding Information: SV: None. AM: Research funding from Celgene Corporation. CDD: Personal fees from Abbvie, personal fees from Agios, personal fees from Novartis, personal fees from ImmuneOnc, personal fees from Daiichi Sankyo, personal fees from Celgene, personal fees from Jazz, personal fees from Notable Labs, outside the submitted work. SL: None. NGD: reports grant from Abbvie, Genentech, Astellas, Daiichi‐Sankyo, Pfizer, BMS, Immunogen, Novimmune, Forty‐seven; personal fees from Abbvie, Genentech, Astellas, Daiichi‐Sankyo, Pfizer, BMS, Immunogen, Jazz pharmaceuticals, Trillium, Forty‐seven, Gilead, Kite, Novartis. TMK: None. CRR: None. YA: None. MO: None. KS: None. NJS: reports grant from Takeda Oncology, Astellas; Personal fees from Takeda Oncology, AstraZeneca, Amgen. KT: has received personal fees for service on advisory boards of Symbio Pharmaceuticals, GSK, Celgene. MY: None. FR: None. HMK: grants and other from AbbVie, grants and other from Agios, grants and other from Amgen, grants from Ariad, grants from Astex, grants from BMS, from Cyclacel, grants from Daiichi‐Sankyo, grants and other from Immunogen, grants from Jazz Pharma, grants from Novartis, grants and other from Pfizer, other from Actinium, other from Takeda, outside the submitted work. MYK: has received grants from NIH, NCI, Abbvie, Genentech, Stemline Therapeutics, Forty‐Seven, Eli Lilly, Cellectis, Calithera, Ablynx, Astra Zeneca; Consulting/honorarium from AbbVie, Genentech, F. Hoffman La‐Roche, Stemline Therapeutics, Amgen, Forty‐Seven, Kisoji; clinical trial support from Ascentage; stocks/royalties in Reata Pharmaceutical. Funding Information: This study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 from the National Cancer Institute and the Research Project Grant Program (R01CA235622) from the National Institutes of Health. We thank the patients, their caregivers, and members of the study team involved in this trial.

PY - 2021/5/1

Y1 - 2021/5/1

UR - http://www.scopus.com/inward/record.url?scp=85101032704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101032704&partnerID=8YFLogxK

U2 - 10.1002/ajh.26122

DO - 10.1002/ajh.26122

M3 - Letter

C2 - 33580980

AN - SCOPUS:85101032704

SN - 0361-8609

VL - 96

SP - E154-E157

JO - American journal of hematology

JF - American journal of hematology

IS - 5

ER -

Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this